NASDAQ:SRNE Sorrento Therapeutics Earnings Date & Estimates $0.0008 0.00 (0.00%) As of 10/9/2026 03:57 PM Eastern Sorrento Therapeutics is expected to report earnings on Friday, November 6, 2026. Research:Profile Upcoming Earnings Announcement Announcement DateNovember 6, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Sorrento TherapeuticsSorrento Therapeutics is expected to post earnings of $0.42 per share on revenue of $18.23 million. Sorrento Therapeutics last reported on August 11, 2023, posting -$0.17 per share and missing the -$0.15 consensus estimate. Sorrento Therapeutics has beaten the consensus EPS estimate in 1 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.42Expected Revenue$18.23 millionRecent Track RecordLast ReportedQ2 2023Last Quarter EPS-$0.17 (Missed by -$0.02)Last Quarter Revenue$15.03 millionEPS Beat Rate1 of last 8 quartersPrepare for the Earnings CallCompany ProfileQ2 2023 Earnings ReportQ1 2023 Earnings ReportQ3 2022 Earnings Report Sorrento Therapeutics Earnings FAQ When does Sorrento Therapeutics report earnings? Sorrento Therapeutics (NASDAQ:SRNE) is estimated to report earnings on Friday, November 6, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Sorrento Therapeutics? Analysts expect Sorrento Therapeutics to post earnings of $0.42 per share for the quarter. How much revenue is Sorrento Therapeutics expected to report? The consensus revenue estimate for Sorrento Therapeutics is $18.23 million for the quarter. Sorrento Therapeutics Earnings HeadlinesSorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comSRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 11 at 1:00 AM | Stansberry Research (Ad)Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSee More Sorrento Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sorrento Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sorrento Therapeutics and other key companies, straight to your email. Email Address About Sorrento TherapeuticsSorrento Therapeutics (NASDAQ:SRNE) is a biotechnology company focused on developing therapies for cancer, chronic pain and other serious medical conditions. The company has historically pursued treatments based on antibody therapeutics, cellular therapies and targeted drug-delivery technologies, with research and development centered primarily in the United States. Sorrento’s development programs have included immuno-oncology and chimeric antigen receptor T-cell (CAR-T) therapies, as well as its Sofusa lymphatic drug-delivery platform. The company has also developed resiniferatoxin (RTX), an investigational non-opioid treatment designed to target severe, chronic pain. Other programs have addressed solid tumors, hematologic cancers and infectious diseases, including COVID-19-related diagnostics and therapeutics. Founded in 2009 and headquartered in San Diego, California, Sorrento has operated primarily as a clinical-stage biotechnology company rather than a commercial pharmaceutical business. Dr. Henry Ji, a co-founder, has historically served as chairman and chief executive officer. Sorrento filed for Chapter 11 bankruptcy protection in 2023, and its securities have since undergone significant changes from their former Nasdaq listing.View Sorrento Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
